Additional Biomarkers beyond RAS That Impact the Efficacy of Cetuximab plus Chemotherapy in mCRC: A Retrospective Biomarker Analysis

PURPOSE: We aimed to identify new predictive biomarkers for cetuximab in first-line treatment for patients with RAS wild-type metastatic colorectal cancer (mCRC). METHODS: The study included patients with KRAS wild-type unresectable liver-limited mCRC treated with chemotherapy with or without cetuxi...

Descripción completa

Detalles Bibliográficos
Autores principales: Zheng, Peng, Liang, Chunmin, Ren, Li, Zhu, Dexiang, Feng, Qingyang, Chang, Wenju, He, Guodong, Ye, Lechi, Chen, Jingwen, Lin, Qi, Yi, Tuo, Ji, Meiling, Niu, Zhengchuan, Jian, Mi, Wei, Ye, Xu, Jianmin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6165607/
https://www.ncbi.nlm.nih.gov/pubmed/30305811
http://dx.doi.org/10.1155/2018/5072987

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6165607/
https://www.ncbi.nlm.nih.gov/pubmed/30305811
http://dx.doi.org/10.1155/2018/5072987

Ejemplares similares